Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab in Previously Treated Waldenstrom Macroglobulinemia
NCT06510491Phase 2Recruiting
- Start
- Dec 2024
- Primary completion
- Apr 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of epcoritamab in Waldenstrom macroglobulinemia (WM). Started Dec 2024; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT06510491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06510491.